Roughly 15 million Americans clock in for night shifts, and the World Health Organization’s cancer research arm has classified that schedule as probably carcinogenic. Now a small but carefully designed trial suggests that something as simple as a 3 mg melatonin tablet, the same dose sold at most drugstores for a few cents a pill, may help the body fight back at the molecular level.
In the 40-person randomized, placebo-controlled study, night shift workers who took melatonin before daytime sleep for four weeks excreted roughly 1.8 times more 8-hydroxy-2-deoxyguanosine (8-OH-dG) in their urine than those who took a placebo. That molecule is a fragment the body discards when repair enzymes successfully cut out and replace oxidized, damaged stretches of DNA. A higher level in urine does not mean more damage is happening. It means more damage is being fixed. The roughly 80 percent increase reported by the authors represents the first randomized evidence that a low-cost supplement can measurably boost DNA repair activity in people whose work schedules suppress their natural melatonin rhythm.
Why this trial was built in the first place
The study, pre-registered as NCT03945955, did not appear out of nowhere. It grew from a line of research that has been tightening the connection between night work, broken circadian clocks, and cancer risk for more than a decade.
An earlier field study by Bhatti and colleagues documented that night work, compared with night sleep, was associated with reduced repair of 8-OH-dG lesions in active workers. A separate controlled laboratory experiment went further: when researchers put volunteers on a simulated night shift schedule, the circadian timing of DNA repair genes in white blood cells shifted and blunted, and unrepaired DNA damage, measured by comet assay, climbed. Together, those findings established a clear biological rationale. Night work does not just correlate with cancer in population surveys. It actively weakens the molecular machinery cells depend on to catch and correct genetic errors.
The IARC’s Volume 124 monograph, which evaluated human, animal, and mechanistic evidence before assigning the Group 2A “probably carcinogenic” label, reinforced the urgency. That designation sits one tier below “carcinogenic” and applies when evidence is strong but not yet conclusive. For the nurses, paramedics, warehouse workers, and factory operators who rotate through overnights, it turned a theoretical worry into an officially recognized hazard.
What the numbers actually show
The 1.8-fold difference in urinary 8-OH-dG is striking, but the authors themselves flagged an important caveat: with only 40 participants, the result was borderline statistically significant. A large effect size in a small sample can land near the threshold of chance, and without a published exact p-value or narrow confidence interval, outside researchers cannot yet run independent sensitivity analyses. The finding could solidify or shrink in a larger replication.
There is also a gap between “more repair over four weeks” and “fewer cancers over a career.” Urinary 8-OH-dG is a well-validated proxy for oxidative DNA repair activity, but no trial has followed melatonin-supplemented night workers long enough to measure hard clinical endpoints like tumor diagnosis rates. Epidemiological studies linking decades of night work to breast, colorectal, and other cancers suggest that cumulative unrepaired damage matters, yet they cannot tell us whether melatonin reverses that trajectory.
Dose and timing raise their own questions. The trial tested one dose (3 mg) at one time point (before daytime sleep). Whether a lower or higher dose would change the outcome, or whether timing relative to the start of the sleep window matters, remains untested. Night shift schedules themselves vary widely. Workers on permanent overnights may respond differently from those on rotating patterns, who tend to experience more severe circadian misalignment.
And the mechanistic bridge is still incomplete. Lab work shows that simulated night shifts disrupt circadian expression of DNA repair genes in leukocytes. A logical next step would be serial gene-expression panels in supplemented workers to confirm that melatonin restores both the amplitude and phase of those repair rhythms, not just the downstream excretion of a single biomarker. That evidence has not yet been published.
Sorting the strong evidence from the preliminary
Three layers of evidence support the headline finding, but they differ in weight.
The strongest is the trial itself. Pre-registration in a public registry means the primary endpoints and analysis plan were locked before data collection ended, reducing the risk that researchers cherry-picked a favorable result after the fact. Publication in a BMJ-group occupational medicine journal adds peer-review scrutiny, though peer review does not guarantee replication.
The second layer is the observational and laboratory groundwork. Bhatti’s field study in active workers and the controlled sleep-lab experiment mapped the pathway from circadian disruption to impaired repair capacity. They are not randomized trials of melatonin, but they make it biologically plausible that restoring a suppressed nighttime hormone signal could help.
The third layer is the broader body of circadian biology. Under normal light-dark cycles, melatonin peaks at night and drops when people are exposed to bright light, as most shift workers are. Animal experiments have shown that suppressed melatonin can accelerate tumor growth, while restoring melatonin rhythms can slow it in certain models. Cell-culture work links melatonin to oxidative stress pathways and DNA repair enzymes, though doses and conditions differ substantially from a human swallowing a 3 mg tablet. This backdrop does not prove the pill will prevent cancer, but it places the new trial within a coherent scientific framework rather than leaving it as an isolated data point.
What this means for people who work nights
For readers trying to weigh the evidence, three questions help organize the picture. Does night work increase cancer risk? The IARC classification, backed by human and experimental data, says it probably does. Does night work impair DNA repair in the short term? Multiple studies, from field observations to controlled lab simulations, point to yes. Can melatonin supplementation meaningfully restore that repair in real-world workers? This trial offers the first randomized support, but with statistical and practical caveats that demand replication in larger, longer studies.
Melatonin at 3 mg is generally considered safe for short-term use in healthy adults, according to the National Institutes of Health’s Office of Dietary Supplements, though it can cause daytime drowsiness, headaches, and dizziness, and it may interact with blood thinners, immunosuppressants, and diabetes medications. Anyone considering supplementation should talk to a clinician first, especially shift workers who may already be managing fatigue-related risks.
The trial does not yet justify blanket melatonin prescriptions as a cancer-prevention strategy. What it does is identify DNA repair as a modifiable target and show that a simple, low-cost intervention can move the needle on a validated biomarker. Future research will need larger samples, longer follow-up, varied dosing protocols, and direct measures of both gene expression and clinical outcomes.
Until those results arrive, the most evidence-backed steps for employers and workers remain minimizing unnecessary night shifts, optimizing workplace lighting, designing schedules that limit circadian disruption, and protecting adequate daytime sleep. Melatonin may eventually join that toolkit. For now, it is the most promising lead the field has produced, and the next round of trials will determine whether it holds up.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
